U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07674134) titled 'Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis' on June 18.
Brief Summary: The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response.
The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.
Study Start Date: April 23, 2024
Study Type: OBSERVATIONAL
Condition:
Rheumatoid Arthritis (RA)
Recruitmen...